Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication. A cohort that included neoadjuvant and adjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jonathan W., Sholl, Lynette M., Dacic, Sanja, Fishbein, Michael C., Murciano-Goroff, Yonina R., Rajaram, Ravi, Szymczak, Sylwia, Szpurka, Anna M., Chao, Bo H., Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232990/
https://www.ncbi.nlm.nih.gov/pubmed/37274265
http://dx.doi.org/10.3389/fonc.2023.1178313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232990/
https://www.ncbi.nlm.nih.gov/pubmed/37274265
http://dx.doi.org/10.3389/fonc.2023.1178313

Ejemplares similares